Leinco Technologies

Anti-Human CD307e (FcRL5) - APC

Product Code:
 
LEI-I-1223
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG2a κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
509F6
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Blocking
  • Flow Cytometry
  • Immunoprecipitation (IP)
Shipping:
 
2-8°C
Storage:
 
This Allophyc°Cyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-I-1223-100ug100 ug£347.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Antigen Distribution:
FcRL5 is expressed on mature B cells and plasma cells.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
Allophycocyanin (APC)
Format:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Cells transfected with Human FcRL5.
Long Description:
FcRL5 antibody, 509F6, recognizes Fc receptor-like 5 (FcRL5), also known as immunoglobulin superfamily receptor translocation associated 2 (IRTA2), Fc receptor homolog 5 (FcRH5), and BXMAS1. FcRL5 is a 106 kDa type I transmembrane glycoprotein containing 9 Ig-like extracellular domains, a cytoplasmic ITAM-like consensus sequence, and two cytoplasmic ITIM-like sequences1. FcRL5 is found on most mature B cells, with the highest levels on naive and memory B cells and plasma cells1,2. FcRL5 is an IgG receptor and binds to all IgG isotypes3, resulting in the inhibition of BCR signaling through the recruitment of SH2 domain-containing tyrosine phosphatase 1 (SHP-1) after tyrosine phosphorylation of its two ITIMs4. B cell malignancies, including multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia, often exhibit aberrant FCRL5 expression, indicating FcRL5 as a potential biomarker or therapeutic target5-7.
NCBI Gene:
83416
Target:
FcRL5

References

1. M. D. Cooper., et al. (2001). Proc. Natl. Acad. Sci. USA 98: 9772?9777 2. Koeppen H., et al. (2006) Int Immunol. 18:1363-1373 3. Colonna M., et al. (2012) J Immunol. 188(10):4741-5 4. M. D. Cooper., et al (2007) Proc. Natl. Acad. Sci. USA 104: 9770?9775 5. Dalla-Favera R., et al. (2001) Immunity. 14(3):277-89 6. Pastan I., et al. (2007) Leukemia. 21(1):169-74 7. Nagata S., et al. (2005) Clin Cancer Res. 11(1):87-96